May 15, 2020 / 6:40 PM / 13 days ago

BRIEF-FDA Approves Clovis Oncology's Rubraca For Certain Prostate Cancer Patients

May 15 (Reuters) - Clovis Oncology Inc:

* RUBRACA® (RUCAPARIB) APPROVED IN THE U.S. AS MONOTHERAPY TREATMENT FOR PATIENTS WITH BRCA1/2-MUTANT, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY

* CLOVIS ONCOLOGY INC - ACCELERATED APPROVAL BASED ON OBJECTIVE RESPONSE RATE (ORR) AND DURATION OF RESPONSE (DOR) DATA FROM TRITON2 CLINICAL TRIAL(I) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below